This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

  1. Home
  2. Professionals
  3. James Halstead
  1. Back
James Halstead
James Halstead
Partner
London +44 20 7067 2052 jhalstead@cov.com Download V-card
View Less

James Halstead is a partner in the Corporate Practice and is resident in Covington's London office.

Mr. Halstead advises on a range of corporate transactions including mergers and acquisitions, initial public offerings, public and private financings, and restructurings.  Mr. Halstead also advises on commercial transactions including technology transfers, intellectual property pipeline arrangements, licensing and joint ventures.

Mr. Halstead acts for companies at all stages of development, as well as investors and management teams.  His practice covers a wide range of industries; he has particular expertise in advising on deals in the life sciences and technology sectors.

  • Advised the management team on The Foundry’s investment from HgCapital under the terms of which HgCapital assumed majority ownership from The Carlyle Group for an enterprise value of £200 million ($312 million USD). The Foundry is a leading provider of award-winning creative software.
  • Advised Nikon Corporation on its €72 million public takeover over of Metris NV, a Belgian metrology company listed on Euronext Brussels.
  • Advised Johnson & Johnson on the sale of its vaccine manufacturing business in Solna, Sweden to Valneva, a French pharmaceutical company listed on Euronext, Paris.
  • Advised OCP S.A. a leading producer of phosphate rock and phosphoric acid, on its acquisition of approximately 10% of the share capital of, and on its entry into a long-term supply agreement with, Brazilian listed fertilizer company, Fertilizantes Heringer S.A.
  • Advised hit musical producer, Cameron Mackintosh Limited, on its acquisition of the Victoria Palace Theatre, London.
  • Advised Axis-Shield plc, on the £235 million all cash public takeover offer from Alere, Inc., a US company listed on the New York Stock Exchange. Axis-Shield develops and manufactures diagnostic testing equipment and was then dual listed in London and Oslo.
  • Advised Spanish pharmaceutical company, Laboratorios Esteve, S.A. in a global multi-programme discovery and development collaboration, with payments potentially exceeding $1 billion, with Mundipharma Laboratories GmbH and its independent associated company, Purdue Pharmaceuticals LP, to bring to market important next generation products for the management of pain.
  • Advised AstraZeneca and MedImmune, its global biologics research and development arm, on the acquisition of Spirogen, a privately-held biotech company focused on antibody-drug conjugate technology for use in oncology.
  • Advised the visual effects (VFX) software company, The Foundry, on its acquisition of Luxology LLC and various other corporate and commercial matters.
  • Advised ReNeuron Group plc, an AIM listed stem cell therapy company, on its £33m fund raising.
  • Advised Imperial Innovations on various investments, including portfolio companies Crescendo Biologics and Inivata.
  • Advising Abingworth on its investment in GammaDelta Therapeutics Ltd, an immunotherapy company.
  • Advised the syndicate of investors, including Imperial Innovations, Johnson & Johnson Innovation – JJDC, Inc., Cambridge Innovation Capital and Woodford Patient Capital Trust, on their £31.5 million Series A investment in Inivata Limited, a clinical cancer genomics company employing the precision of ctDNA analysis to improve personalized healthcare in oncology.
  • Advised Kesios Therapeutics on its £19 million Series A financing by a syndicate of investors including SVLS, Imperial Innovations and Abingworth. Kesios is developing novel therapeutics for the treatment of multiple myeloma and other cancers.
  • Advised Johnson & Johnson on the acquisition of XO1 Limited, an asset-centric biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab.
  • Advised GammaDelta Therapeutics Limited on a strategic collaboration with Takeda to develop GammaDelta Therapeutics’ novel T cell platform, which is based on the unique properties of gamma delta (γδ) T cells derived from human tissues.
View More View Less
View Less
  • LMG Life Sciences Europe, Life Sciences Star - Financial & Transactional (United Kingdom) (2014-2015)
  • Super Lawyers - London, Corporate Finance (2013)
  • Chambers UK, Private Equity: Venture Capital Investment (2016-2017)
  • Chambers UK, Life Sciences: Transactional (2011-2012)    
  • Legal 500 UK, M&A - Upper Mid-Market & Premium Deals (2013, 2016)
  • Legal 500 UK, Venture Capital (2012, 2016)
  • Legal 500 UK, Media & Entertainment (2015)   
  • Legal 500 UK, Equity Capital Markets (2012)  
  • Legal 500 UK, Flotations, Small and Mid-Cap (2011-2012)
  • Legal 500 UK, Pharmaceuticals and Biotechnology (2011)

Practices

Industries

Education

College of Law, Chester, L.P.C., 1998

College of Law, Chester, C.P.E., 1997

University of Cambridge, B.A., 1996

Bar Admissions

  • Solicitor of the Senior Courts of England and Wales